Seattle, United States
Tune Therapeutics, with its slogan "Mastering the epigenome, unlocking complex disease," is making significant strides in the biotechnology industry since its founding in 2020. Headquartered in the United States, the company is at the forefront of epi-therapeutic medicine development. Its proprietary platform, TEMPO, offers a novel approach to genetic tuning by adjusting gene expression levels without altering the DNA permanently. This method presents a transformative potential in treating complex diseases such as cancer, genetic disorders, and conditions related to aging, broadening the scope of genetic medicine.
The company recently secured a $175.00M Series B investment on January 1, 2025, with notable participation from investors such as NEA, Regeneron Pharmaceuticals, Yosemite, and Hevolution. With this substantial backing, Tune Therapeutics is well-positioned to advance its research and development efforts, poised to make a considerable impact on healthcare by addressing numerous currently incurable diseases.
